

**REMARKS**

In this Preliminary Amendment, the claims have been amended to conform with the issued claims in related U.S. Patent No. 7,078,165.

Claims 1-34 have been cancelled. Claims 35-49 are new.

Support for new claims 35-49 can be found throughout the specification, for example, as follows:

**Claim**    **Support**

- |    |  |
|----|--|
| 35 | Original claim 15; page 3, lines 24-28; page 4, lines 7-14; page 4, lines 18-24; page 8, line 29 - page 9, line 3; page 25, line 28 - page 26, line 5; Figure 5a |
| 36 | Original claim 15; page 3, lines 24-28; page 4, lines 7-14; page 4, lines 18-24; page 8, line 29 - page 9, line 3; page 25, line 28 - page 26, line 5; Figure 5a |
| 37 | Original claim 15; page 3, lines 24-28; page 4, lines 7-14; page 4, lines 18-24; page 8, line 29 - page 9, line 3; page 25, line 28 - page 26, line 5; Figure 5a |
| 38 | Original claim 15; page 3, lines 24-28; page 4, lines 7-14; page 4, lines 18-24; page 25, line 28 - page 26, line 5; Figure 5a                                   |
| 39 | Original claims 11-13 and 16; page 4, lines 7-14; page 8, line 29 - page 9, line 3   |
| 40 | Original claims 11-13 and 16; page 4, lines 7-14; page 8, line 29 - page 9, line 3   |
| 41 | Original claims 11-13 and 16; page 4, lines 7-14; page 8, line 29 - page 9, line 3   |
| 42 | Original claim 18; page 4, lines 28-31   |
| 43 | Original claim 18; page 4, lines 28-31   |

Claim    Support

- |    |   |
|----|---|
| 44 | Original claims 11-13 and 18; page 4, lines 28-31 |
| 45 | Original claims 11-13 and 18; page 4, lines 28-31 |
| 46 | Original claims 11-13 and 18; page 4, lines 28-31 |
| 47 | Original claims 11-13 and 18; page 4, lines 28-31 |
| 48 | Original claims 11-13 and 18; page 4, lines 28-31 |
| 49 | Original claim 17; page 4, lines 25-27            |

Applicant submits that these claim amendments are fully supported by the specification, do not introduce new matter or require a further search of the art, and respectfully request their entry.

In a Response to Restriction Requirement filed December 12, 2007, Applicant elected Group IV, drawn to a method for enhancing the immune response of a host, with traverse. Applicant also elected to prosecute the species L-Ala-D-Glu-mesoDAP, without traverse.

Applicant contended that there is unity of invention among Group IV (drawn to a method for enhancing the immune response of a host comprising administering an antigen and a molecule related to MTP and compositions thereof), Group V (a method for providing an immune response in a host comprising administering a molecule related to MTP and compositions thereof), and Group VI (drawn to method of vaccination comprising administering a molecule related to MTP and compositions thereof),

because all of the claims in these groups are directed to the use of a molecule related to muramyl tripeptide (MTP) to induce an immune response.

Applicant respectfully submits that new claims 35-38 belong to elected Group IV, new claims 39-43 belong to Group V, and new claims 44-49 belong to Group VI. The elected species reads on each of claims 35-49.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

*William B. Raich*

Dated: January 23, 2008

By: William B. Raich Reg. No. 54,786  
Kenneth J. Meyers  
for: Reg. No. 25,146  
Phone: 202-408-4033  
Fax: 202-408-4400  
E-mail: ken.meyers@finnegan.com